Biogen Hemophilia A Therapy Helps in Fewer Injections

Biogen Idec Inc. and partner Swedish Orphan Biovitrum AB said their hemophilia A therapy controlled bleeding with fewer injections in a late-stage study. The companies plan to apply for U.S. approval early next year.

The therapy, long-lasting recombinant Factor VIII Fc fusion protein, or rFVIIIFc, yielded annual rates of 1.6 bleeds in a preventive treatment study arm in which patients received the drug about once every three and a half days. That compared with